221 related articles for article (PubMed ID: 26422251)
1. Impact of Alemtuzumab Therapy and Route of Administration in T-Prolymphocytic Leukemia: A Single-Center Experience.
Damlaj M; Sulai NH; Oliveira JL; Ketterling RP; Hashmi S; Witzig T; Nowakowski G; Call TG; Shanafelt TD; Ding W; Hogan WJ; Litzow MR; Patnaik MM
Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):699-704. PubMed ID: 26422251
[TBL] [Abstract][Full Text] [Related]
2. Allogeneic hematopoietic cell transplantation in T-cell prolymphocytic leukemia: A single-center experience.
Dholaria BR; Ayala E; Sokol L; Nishihori T; Chavez JC; Hussaini M; Kumar A; Kharfan-Dabaja MA
Leuk Res; 2018 Apr; 67():1-5. PubMed ID: 29407180
[TBL] [Abstract][Full Text] [Related]
3. Sequential chemoimmunotherapy of fludarabine, mitoxantrone, and cyclophosphamide induction followed by alemtuzumab consolidation is effective in T-cell prolymphocytic leukemia.
Hopfinger G; Busch R; Pflug N; Weit N; Westermann A; Fink AM; Cramer P; Reinart N; Winkler D; Fingerle-Rowson G; Stilgenbauer S; Döhner H; Kandler G; Eichhorst B; Hallek M; Herling M
Cancer; 2013 Jun; 119(12):2258-67. PubMed ID: 23512246
[TBL] [Abstract][Full Text] [Related]
4. High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H.
Dearden CE; Matutes E; Cazin B; Tjønnfjord GE; Parreira A; Nomdedeu B; Leoni P; Clark FJ; Radia D; Rassam SM; Roques T; Ketterer N; Brito-Babapulle V; Dyer MJ; Catovsky D
Blood; 2001 Sep; 98(6):1721-6. PubMed ID: 11535503
[TBL] [Abstract][Full Text] [Related]
5. Loss of donor chimerism in remission after allogeneic stem cell transplantation of T-prolymphocytic leukemia patients following alemtuzumab induction therapy.
Szuszies CJ; Hasenkamp J; Jung W; Koch R; Trümper L; Wulf GG
Int J Hematol; 2014 Nov; 100(5):425-8. PubMed ID: 25258193
[TBL] [Abstract][Full Text] [Related]
6. New lessons learned in T-PLL: results from a prospective phase-II trial with fludarabine-mitoxantrone-cyclophosphamide-alemtuzumab induction followed by alemtuzumab maintenance.
Pflug N; Cramer P; Robrecht S; Bahlo J; Westermann A; Fink AM; Schrader A; Mayer P; Oberbeck S; Seiler T; Zenz T; Dürig J; Kreuzer KA; Stilgenbauer S; Eichhorst B; Hallek M; Herling M; Hopfinger G
Leuk Lymphoma; 2019 Mar; 60(3):649-657. PubMed ID: 30234404
[TBL] [Abstract][Full Text] [Related]
7. Alemtuzumab therapy in T-cell prolymphocytic leukemia: comparing efficacy in a series treated intravenously and a study piloting the subcutaneous route.
Dearden CE; Khot A; Else M; Hamblin M; Grand E; Roy A; Hewamana S; Matutes E; Catovsky D
Blood; 2011 Nov; 118(22):5799-802. PubMed ID: 21948296
[TBL] [Abstract][Full Text] [Related]
8. Advances and Perspectives in the Treatment of T-PLL.
Braun T; von Jan J; Wahnschaffe L; Herling M
Curr Hematol Malig Rep; 2020 Apr; 15(2):113-124. PubMed ID: 32034661
[TBL] [Abstract][Full Text] [Related]
9. Patterns of Late Relapse after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with T-Cell Prolymphocytic Leukemia.
Shumilov E; Hasenkamp J; Szuszies CJ; Koch R; Wulf GG
Acta Haematol; 2021; 144(1):105-110. PubMed ID: 32259827
[TBL] [Abstract][Full Text] [Related]
10. Stem cell transplantation after alemtuzumab in T-cell prolymphocytic leukaemia results in longer survival than after alemtuzumab alone: a multicentre retrospective study.
Krishnan B; Else M; Tjonnfjord GE; Cazin B; Carney D; Carter J; Ketterer N; Catovsky D; Ethell M; Matutes E; Dearden CE
Br J Haematol; 2010 Jun; 149(6):907-10. PubMed ID: 20201944
[No Abstract] [Full Text] [Related]
11. Allogeneic hematopoietic stem cell transplantation for T-prolymphocytic leukemia: a report from the French society for stem cell transplantation (SFGM-TC).
Guillaume T; Beguin Y; Tabrizi R; Nguyen S; Blaise D; Deconinck E; Redjoul R; Cornillon J; Guillerm G; Contentin N; Sirvent A; Turlure P; Salmon A; Huynh A; François S; Peffault de Latour R; Yakoub-Agha I; Mohty M
Eur J Haematol; 2015 Mar; 94(3):265-9. PubMed ID: 25130897
[TBL] [Abstract][Full Text] [Related]
12. Effect of allogeneic hematopoietic cell transplantation for patients with T-prolymphocytic leukemia: a retrospective study from the Adult Lymphoma Working Group of the Japan Society for hematopoietic cell transplantation.
Yamasaki S; Nitta H; Kondo E; Uchida N; Miyazaki T; Ishiyama K; Kiyota M; Matsuoka H; Ichinohe T; Fukuda T; Atsuta Y; Suzumiya J; Suzuki R
Ann Hematol; 2019 Sep; 98(9):2213-2220. PubMed ID: 31327025
[TBL] [Abstract][Full Text] [Related]
13. T-cell prolymphocytic leukemia.
Khot A; Dearden C
Expert Rev Anticancer Ther; 2009 Mar; 9(3):365-71. PubMed ID: 19275513
[TBL] [Abstract][Full Text] [Related]
14. Are we improving the outcome for patients with T-cell prolymphocytic leukemia by allogeneic stem cell transplantation?
Herling M
Eur J Haematol; 2015 Mar; 94(3):191-2. PubMed ID: 25712069
[No Abstract] [Full Text] [Related]
15. A case report of T cell prolymphocytic leukemia and Kaposi sarcoma and a review of T cell prolymphocytic leukemia.
Paul RN; Alizadeh L; Ajayi OI; Karpurapu H; Ganesan C; Taddesse-Heath L; Aggarwal A
Acta Haematol; 2012; 127(4):235-43. PubMed ID: 22517037
[TBL] [Abstract][Full Text] [Related]
16. T-cell prolymphocytic leukaemia (T-PLL): a rare disease with a grave prognosis.
Vivekanandarajah A; Atallah JP; Gupta S
BMJ Case Rep; 2013 May; 2013():. PubMed ID: 23645660
[TBL] [Abstract][Full Text] [Related]
17. Characteristics, outcomes, prognostic factors and treatment of patients with T-cell prolymphocytic leukemia (T-PLL).
Jain P; Aoki E; Keating M; Wierda WG; O'Brien S; Gonzalez GN; Ferrajoli A; Jain N; Thompson PA; Jabbour E; Kanagal-Shamanna R; Pierce S; Alousi A; Hosing C; Khouri I; Estrov Z; Cortes J; Kantarjian H; Ravandi F; Kadia TM
Ann Oncol; 2017 Jul; 28(7):1554-1559. PubMed ID: 28379307
[TBL] [Abstract][Full Text] [Related]
18. Alemtuzumab (anti-CD52 monoclonal antibody) as single-agent therapy in patients with relapsed/refractory chronic lymphocytic leukaemia (CLL)-a single region experience on consecutive patients.
Eketorp Sylvan S; Lundin J; Ipek M; Palma M; Karlsson C; Hansson L
Ann Hematol; 2014 Oct; 93(10):1725-33. PubMed ID: 24844780
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic therapy overcomes treatment resistance in T cell prolymphocytic leukemia.
Hasanali ZS; Saroya BS; Stuart A; Shimko S; Evans J; Vinod Shah M; Sharma K; Leshchenko VV; Parekh S; Loughran TP; Epner EM
Sci Transl Med; 2015 Jun; 7(293):293ra102. PubMed ID: 26109102
[TBL] [Abstract][Full Text] [Related]
20. [Successful Treatment of T-Cell Prolymphocytic Leukemia with Alemtuzumab].
Ueki D; Yoshida C; Tsutsumi Oota I; Seki M; Komeno T; Ito H; Ide Y
Gan To Kagaku Ryoho; 2019 May; 46(5):913-915. PubMed ID: 31189814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
